Author/Editor		Josić, D; Schulz, P; Biesert, L; Hoffer, L; Schwinn, H; Kordiš-Krapež, M; Štrancar, A
Title		Issues in the development of medical products based on human plasma
Type		članek
Source		J Chromatogr B Biomed Appl
Vol. and No.		Letnik 694, št. 2
Publication year		1997
Volume		str. 253-69
Language		eng
Abstract		Product development and process validation are shown in the case of several products obtained from human plasma. These are virus-inactivated plasma, intravenous immunoglobulins and the clotting factors VIII and IX. Different analytical methods are presented, which are used for product control and in-process control. For the production of virus-inactivated human plasma a down-scale protocol is presented, allowing a simulation of the production on a laboratory scale. Virus validation has shown that the reduction of transfusion-relevant viruses in the process was higher than six log steps. Determination of leachables from the RP-column, which was used in this production, proved that they appear in the final product in quantities below the detection limits only. It was also shown that the chemicals used for virus inactivation could be quantitatively removed from the product. For the isolation of other products, here intravenous gamma globulins and the clotting factors VIII and IX, similar validation steps had to be taken. In the case of clotting factor VIII the following data were determined, the reduction of viruses, the amount of leachables from the column, the residues of chemicals from the solvent/detergent treatment for virus inactivation. Virus reduction was successfully performed as well as the removal of chemicals used for virus inactivation. The amount of leachables from the columns used for chromatographic purification was found to be far below the permissible levels.
Descriptors		BLOOD PROTEINS BIOLOGICAL PRODUCTS PLASMA VIRUSES VIRUS DISEASES SAFETY REPRODUCIBILITY OF RESULTS OCTOXYNOL DRUG CONTAMINATION DETERGENTS CHROMATOGRAPHY, ION EXCHANGE CHROMATOGRAPHY, AFFINITY